Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 10/20 | 0.54 |
| ▸ | PLAU | P00749 | 4/20 | 0.45 |
| ▸ | F2 | P00734 | 3/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30258337 | 1.00 | ELANE (0.54) | ELANEPLAUF2PDGFRACDK5 | |
| SCHEMBL17419175 | 0.88 | ELANE (0.64) | ELANEPLAUF2KDM4EL3MBTL1 | |
| SCHEMBL31646748 | 0.88 | ELANE (0.64) | ELANEPLAUF2KDM4EL3MBTL1 | |
| SCHEMBL9959858 | 0.85 | ELANE (0.57) | ELANEPLAUF2MAPT | |
| SCHEMBL492125 | 0.83 | PDGFRA (0.47) | ELANEPDGFRACDK5TYRO3KDM4E | |
| SCHEMBL19128015 | 0.82 | ELANE (0.45) | ELANEPLAUF2KDM4EL3MBTL1 | |
| SCHEMBL498197 | 0.82 | ELANE (0.51) | ELANEPLAUF2PDGFRACDK5 | |
| SCHEMBL14011218 | 0.81 | ELANE (0.44) | ELANEPLAUF2KDM4EHTR3A | |
| SCHEMBL19127362 | 0.81 | ELANE (0.50) | ELANEPLAUF2PDGFRACDK5 | |
| SCHEMBL22031821 | 0.80 | ALDH1A1 (0.44) | ELANEPLAUF2KDM4EHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720041-A2 | N-(1H-INDOL-2-YL)METHYL)-4-ETHYNYL-PICOLINAMIDE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Allorion Therapeutics Inc (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20250026763-A1 | EGFR INHIBITORS AND METHODS OF USE THEREOF | Allorion Therapeutics Inc | 2025-01-23 | — | — | US | disclosed |
| WO-2024240241-A2 | EGFR INHIBITORS AND METHODS OF USE THEREOF | Allorion Therapeutics Inc (US) | 2024-11-28 | — | — | WO | disclosed |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-29 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-4400503-A2 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3246070-B1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING AZOLES | GILEAD SCIENCES INC (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
| EP-2029558-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2009012125-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2008-12-11 | — | — | US | disclosed |
| EP-1984360-A2 | COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS | Eli Lilly & Company (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007092751-A2 | COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270460-A1 | FXR AGONISTS | NR1H4, SLC10A1, GPBAR1 | ELANE 2366/4885PLAU 2629/4885F2 1022/4885 |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | F2R, TBXA2R, PTAFR | ELANE 673/4885PLAU 232/4885F2 10/4885 |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | ELANE 1755/4885PLAU 4434/4885F2 4785/4885 |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | ELANE 2518/4885PLAU 4762/4885F2 4862/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | ELANE 1755/4885PLAU 4434/4885F2 4785/4885 |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | ELANE 2182/4885PLAU 2191/4885F2 1141/4885 |
| US-20250026763-A1 | EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB3, ERBB2 | ELANE 2417/4885PLAU 2629/4885F2 4573/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | ELANE 1755/4885PLAU 4434/4885F2 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.